Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

NCT01032070 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class

Stopped In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, it has been stopped.

Conditions

Interventions

Sponsor

OSI Pharmaceuticals